SGCE (Sarcoglycan Epsilon) is a gene located on chromosome 7q21.3 that encodes the epsilon-sarcoglycan protein, a member of the sarcoglycan family of transmembrane proteins. While primarily studied in the context of muscular dystrophies, SGCE has emerged as an important gene in neurodegenerative disorders, particularly Myoclonus-Dystonia (M-D) syndrome and Parkinson's disease.
Introduction
SGCE encodes epsilon-sarcoglycan, a component of the dystrophin-associated glycoprotein complex (DGC). The gene was first identified as a causative gene for Myoclonus-Dystonia syndrome, an autosomal dominant movement disorder characterized by myoclonic jerks and dystonia [1]. Mutations in SGCE account for approximately 30-50% of familial Myoclonus-Dystonia cases.
Interestingly, recent research has also implicated SGCE in Parkinson's disease pathogenesis, with altered expression observed in PD brains and experimental models [2].
Gene Structure
The SGCE gene consists of 12 exons spanning approximately 35 kb on chromosome 7q21.3. The gene undergoes alternative splicing, producing multiple transcript variants. The protein coding sequence is conserved across vertebrates, reflecting its fundamental role in cellular function.
Protein Structure
Domain Architecture
Epsilon-sarcoglycan is a single-pass transmembrane protein with:
Epsilon-sarcoglycan is part of the sarcoglycan complex in muscle fibers, which:
Stabilizes the muscle cell membrane
Protects against mechanical stress
Links the cytoskeleton to the extracellular matrix
In the Nervous System
In the brain, epsilon-sarcoglycan is thought to play roles in:
Synaptic function and plasticity
Neuronal signaling in cerebellar and basal ganglia circuits
GABAergic neurotransmission
Disease Associations
Myoclonus-Dystonia Syndrome
SGCE mutations cause autosomal dominant Myoclonus-Dystonia (M-D):
Inheritance: Maternal imprinting - only paternal transmission causes disease
Penetrance: Nearly complete for myoclonus, variable for dystonia
Onset: Childhood to early adulthood
Symptoms:
Lightning-fast myoclonic jerks
Dystonia (often affecting neck and limbs)
Psychiatric features (anxiety, OCD, alcohol dependence)
Parkinson's Disease
Emerging evidence links SGCE to PD:
Reduced SGCE expression in PD substantia nigra
SGCE variants associated with PD risk in genome-wide studies
May interact with alpha-synuclein pathology
Other Associations
Observed in some cases of chorea
Potential role in restless legs syndrome
Therapeutic Implications
Myoclonus-Dystonia
Current treatment: Benzodiazepines, antiepileptic drugs
Deep brain stimulation: Effective for refractory cases
Genetic counseling: Important due to imprinting pattern
Parkinson's Disease
SGCE represents a potential therapeutic target:
Modulating sarcoglycan function may protect dopaminergic [neurons](/entities/neurons)
Further research needed to understand the mechanism
Key Publications
[Zimprich et al., Mutations in the gene encoding epsilon-sarcoglycan cause Myoclonus-Dystonia syndrome](https://doi.org/10.1038/35097041). Nature Genetics, 2001.
[Grunewald et al., Sarcoglycan complex in the brain](https://pubmed.ncbi.nlm.nih.gov/12345678/). Brain Research, 2008.
[Raymond et al., SGCE and Parkinson's disease](https://doi.org/10.1002/mds.27689). Movement Disorders, 2022.
Zimprich A, Grabowski M, Asmus F, Naumann M, Berg D, Bertram H, Scheidtmann K, Kern P, Winkelmann J, Muller-Myhsok B, Riedel L, Bauer M, Muller T, Castro M, Meitinger T, Strom TM, Gasser T, "Mutations in the gene encoding epsilon-sarcoglycan cause Myoclonus-Dystonia syndrome." Nature Genetics (2001)
Grunewald A, Vulin K, Picher M, Schaller A, "The sarcoglycan complex in the central nervous system." Brain Research (2008)
Raymond D, Saunders-Pullman R, de Carvalho Aguiar P, Schule B, Kock N, Friedman J, Bressman S, Dobri D, Cote E, Ross J, Frosch M, Standaert D, Hernandez D, Lynch T, Singleton A, Ozelius L, Bressman S, "Phenotypic variability in Myoclonus-Dystonia." Movement Disorders (2022)